# Safety Study of PP-007 in Subjects With Acute Ischemic Stroke

> **NCT04677777** · PHASE1 · COMPLETED · sponsor: **Prolong Pharmaceuticals** · enrollment: 24 (actual)

## Conditions studied

- Acute Ischemic Stroke

## Interventions

- **BIOLOGICAL:** PP-007 (Two doses administered 24±6 hours apart) + SOC (IVT or MT or IVT+MT)

## Key facts

- **NCT ID:** NCT04677777
- **Lead sponsor:** Prolong Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-04-24
- **Primary completion:** 2025-02-20
- **Final completion:** 2025-02-20
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2025-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04677777

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04677777, "Safety Study of PP-007 in Subjects With Acute Ischemic Stroke". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04677777. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*